IXICO plc

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:17 2024-05-21 am EDT			5-day change	1st Jan Change
7.125 ^GBX	-3.39%		-3.39%	-43.00%

05:31pm	EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss	AN
08:09am	Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP2.5M	MT

IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021

April 26, 2021 at 02:00 am EDT

IXICO plc updated ahead of results for the six months ended 31 March 2021. Revenues expected to be £4.9 million for 6 months to 31 March 2021 (2019: £4.6 million), representing 8% growth.

Latest news about IXICO plc

EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss	11:31am	AN
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP2.5M	02:09am	MT
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Loss GBX-2.92	02:08am	MT
Ixico inks supply agreement with Life Molecular Imaging for Neuraceq	Apr. 15	AN
IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer	Apr. 15	CI
Ixico inks collaboration with IMEKA Solutions	Apr. 03	AN
IXICO plc Announces Collaboration Agreement with IMEKA Solutions Inc. to Provide Access to Imeka's Suite of Services for White Matter Imaging deployed in Alzheimer's Disease and Multiple Sclerosis Clinical Trials, Amongst Other CNS Indications	Apr. 03	CI
Ixico shares fall 20% as revenue to decline, hit by delays to projects	Mar. 13	AN
AIM WINNERS & LOSERS: Woodbois rises as plots Mozambique exit	Mar. 13	AN
FTSE 100 slips but CAC and DAX hit record highs	Mar. 13	AN
Ixico CEO Cerroni to retire by end of 2024; starts succession search	Jan. 12	AN
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024	Jan. 12	CI
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024	Jan. 12	CI
Transcript : IXICO plc, 2023 Earnings Call, Dec 05, 2023	Dec. 05
EARNINGS AND TRADING: Ixico revenue falls, Solid State boosts profit	Dec. 05	AN
IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 05	CI
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees	23-10-05	CI
EARNINGS AND TRADING: Barkby revenue dips; Ixico hurt by trial delays	23-09-29	AN
IXICO plc Provides Earnings Guidance for the Full Year of 2023	23-09-29	CI
Andrada raises GBP7.7 million; Ixico signs contract	23-07-18	AN
IXICO plc Announces Contract Win for A Phase 3 Progressive Supranuclear Palsy Study	23-07-18	CI
IXICO Receives New GBP2 Million Imaging Services Contract	23-06-14	MT
Ixico wins Huntington's disease contract worth GBP2 million	23-06-14	AN
IXICO plc Announces Contract Win in Huntington's Disease	23-06-14	CI
Transcript : IXICO plc, H1 2023 Earnings Call, May 23, 2023	23-05-23

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Sector

Biotechnology & Medical Research

Calendar

02:00am - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for IXICO plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IXICO PLC	-43.00%	4.53M
MODERNA, INC.	+41.32%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-1.19%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.09%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-22.42%	19B
BIO-TECHNE CORPORATION	+7.75%	13B
MEDPACE HOLDINGS, INC.	+28.88%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.14%	12.19B

Other Biotechnology & Medical Research

IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021

Latest news about IXICO plc

Chart IXICO plc

Company Profile

Income Statement Evolution

Ratings for IXICO plc

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research